Butein

• Description :

  Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4[1]. Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells[2]. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a[3]. Butein is a SIRT1 activator (STAC) .

• CAS Number :

  [487-52-5]

• Product Name Alternative :

  2’,3,4,4’-tetrahydroxy Chalcone

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Autophagy; EGFR; Phosphodiesterase (PDE)

• Type :

  Natural Products

• Related Pathways :

  Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Butein.html

• Purity :

  99.64

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  OC1=CC=C(C(/C=C/C2=CC(O)=C(O)C=C2)=O)C(O)=C1

• Molecular Formula :

  C15H12O5

• Molecular Weight :

  272.25

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Yu SM, et al. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor.Eur J Pharmacol. 1995 Jun 23;280 (1) :69-77.|[2]Yang EB, et al. Butein, a specific protein tyrosine kinase inhibitor.Biochem Biophys Res Commun. 1998 Apr 17;245 (2) :435-8.|[3]Zhang L, et al. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.Int J Mol Med. 2015 Oct;36 (4) :957-66.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  No Development Reported

• Isoform :

  EGFR/ErbB1/HER1; PDE4